A Randomized,Parallel Controlled,Multicentre,Phase II Study of Apatinib Plus POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) Versus POF in Patients With Advanced/Metastatic Bastric Cancer
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Gimeracil/oteracil/tegafur; Levofolinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 14 Oct 2019 New trial record